Mabion
  • Company
    • About us
      • History
      • Leaderships
      • Team
      • EU grants
      • Requests for Proposal
      • Sustainability – ESG
      • Bussines strategy
      • Quality policy
      • Virtual Tour
    • Investors
      • Corporate documents
      • Shareholders and shares
      • Periodic reports
      • Current reports
      • Sustainability reports
      • Corporate governance at Mabion
      • Financial data
      • For Investors
      • Calendar
  • Resources
    • Science Hub
    • Press releases
    • News
    • Events
    • Media kit
  • Services
    • Process Development
    • Analytics 
    • Drug Substance Manufacturing
  • Contact
    • Contact form
    • Contact for investors
    • Contact for media
    • Careers
  • Science News
  • Resources

Bispecific antibody

Popular receptor targets for oncologic bispecific antibodies

Oncologic Bispecific Antibodies in Immunotherapy

Biologics, Bispecific antibody, Cancer, Drug development
innovative biologics 2026

Innovative Biologics Expected Approvals in 2026

Antibody-drug conjugates, Biologics, Bispecific antibody, Clinical trials, EMA, FDA, Monoclonal antibody, Vaccines
Innovative biologics that are expected to be approved in 2025

Innovative Biologics – Expected Drug Approvals in 2025

Antibody-drug conjugates, Biologics, Bispecific antibody, Clinical trials, EMA, FDA, Monoclonal antibody, Vaccines

Contact

Find out how we may support your business.

bd@mabion.eu

Mabion

gen. Mariana Langiewicza 60
95-050 Konstantynów Łódzki
Poland

+48 42 207 78 90

    Mabion
    • Privacy policy
    • CDMO
    • Media kit
    • Press releases
    • Events

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. HTML Sitemap

    Powered by

    Veneo